Kalray Showcases Leading Solutions for High-performance Computing and Unstructured Data at Dell Technologies World 2023
27.4.2023 18:45:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL) , a leading provider of hardware and software technologies and solutions for high-performance data-centric computing markets, from Cloud to Edge, is pleased to announce its presence at Dell Technologies World as a Dell ETC Partner, from May 22 to 25, 2023, in Las Vegas.
Dell Technologies World (DTW) is a major annual event that brings together industry leaders, experts, and customers to discuss the latest trends and innovations in technology. The event covers a wide range of topics and attracts thousands of attendees from around the world.
Kalray will be exhibiting at DTW as a Dell Technologies ETC Partner. The ETC program is a Dell Technologies partnership program delivering all-in-one solutions, combining selected ETC partner solutions with Dell Technologies servers, storage, and networking, to create an industry-leading value proposition.
With its solutions, Kalray addresses the challenges of data-intensive workloads for use cases such as Artificial Intelligence, Machine Learning, High-Performance Computing, IoT processing, and unstructured data. Primary verticals are Life Sciences, Manufacturing, Higher Education, and Finance. All have requirements to process and manage unstructured data in a fast and efficient way, wherever the data resides.
“This is a great opportunity for Kalray to demonstrate our unique portfolio for HPC and Unstructured Data Solutions, to enterprise customers," says Kalray CEO, Éric Baissus. “The exhibition booth and joint presentation activities at Dell Technologies World is part of our strategy to accelerate our go-to-market and strengthen our offering with Dell Technologies."
pixstor™ with ngenea® , combined with Dell Technologies solutions, provides customers an all-in-one, easy-to-use solution that meets the requirements of demanding storage workloads. pixstor’s™ “Tier-Zero” scratch storage enables customers to dramatically increase storage performance, while ngenea® vastly improves efficiency by consolidating storage environments such as Dell PowerScale and ECS, simplifying data management workflows.
Associated with Kalray’s DPU-based cards , Kalray provides a unique hardware and software storage offering.
At Dell Technologies World, attendees can learn more about Kalray’s award-winning solutions at booth #1729. The Kalray team will be showcasing several live product demos:
- pixstor™ Search finds data across an entire data namespace, without opening a single file. Bring users closer to their data and reducing time spent locating files.
- Discover ngenea®2 self-service for the world of HSM (Hierarchical storage Management). Watch live as ngenea®2 controls site-to-site replication and cloud bursting, without needing administrative privileges or cloud expertise.
- Global Sync- Distributed workflow challenges call for a distributed workflow solution. Keep your global footprint in sync and up to date, even with hundreds of thousands of changes per hour.
- Kalray will be also introducing a high-performance NVMe-based Tier-0 storage solution based on its DPU (Data Processing Unit) acceleration cards and Dell Technologies server. Designed for data-intensive workloads and applications, this solution offers unique benefits in term of performance per watt and performance per dollar.
Register your interest in our product showcase or book a meeting with our technical experts here:
https://www.kalrayinc.com/dtw-2023
About KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data centric computing markets, from Cloud to Edge. Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures.
Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Sciences, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005601/en/
Contact information
INVESTOR CONTACTS
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
Phone: + 33 4 76 18 90 71
ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Phone: + 33 1 53 67 36 72
PRESS CONTACTS
Sylvie DAM
communication@kalrayinc.com
Phone: +33 4 76 18 90 71
ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Phone: +33 4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom